Sells pain treatments, surgical devices and fracture-healing products to physicians, hospitals and patients.
10-K for FY2025, filed Mar 5, 2026We are a global medical device company focused on helping patients recover and live life to the fullest by relieving pain and addressing…View ↗
Pain Treatments, consisting of: Knee Osteoarthritis (“KOA”): Our product portfolio includes a range of intra-articular, hyaluronic acid…View ↗
We offer a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across…View ↗
The company sells medical products to healthcare providers, institutions, patients and distributors. Most products are billed at shipment or patient acceptance; hospitals are billed for consigned bone grafts when used in surgery.
10-K for FY2025, filed Mar 5, 2026The Company derives revenue primarily from product sales in its (i) Pain Treatments portfolio, which includes osteoarthritic (“OA”) pain…View ↗
Pain TreatmentsView ↗
Most of the Company’s product sales related to bone graft substitutes are through consignment inventory with hospitals, where ownership…View ↗
The Company recognizes revenue from third-party payers, such as governmental agencies, insurance companies or managed care providers, when…View ↗
10-K for FY2025, filed Mar 5, 2026
FY2025 revenue by reportable segment ↗$568.1M
10-K for FY2025, filed Mar 5, 2026
$568.1M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
U.S.
Sold outright
10-K for FY2025, filed Mar 5, 2026 |
88%
FY2022: 89%
|
U.S., FY2025
$502.1M Sources
|
Sold outright |
|
International
Sold outright
|
12%
FY2022: 11%
|
International, FY2025
$66M Sources
|
Sold outright |
The company sells directly to healthcare institutions, patients and healthcare providers, and some surgical products reach hospitals through independent distributors. In certain international markets, distributors sell to physicians.
10-K for FY2025, filed Mar 5, 2026
10-K for FY2025, filed Mar 5, 2026
The Company attributes net sales to external customers to the U.S. and to all foreign countries based on the legal entity from which the…View ↗
Yes. It kept 4 cents of every revenue dollar as net income in FY2025 and turned 13 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 2, 2026
Open tableView ↗
8-K, filed Aug 5, 2026
Q2 reported revenue of $153.2 million increased 4% Q2 GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings…View ↗
Growing. Revenue grew 32% in 4 years, from $430.9M in FY2021 to $568.1M in FY2025, about 7% a year.
New nerve-stimulation products
The older report described TalisMann as still in development and not cleared; the latest says TalisMann and StimTrial were cleared and began limited sales.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 5, 2026The TalisMann® Pulse Generator and Receiver (not yet cleared by FDA) is an accessory to the StimRouter® PNS system and is designed to…View ↗
Restorative portfolio narrowed
The older report described restorative therapies as including devices to restore leg or hand function; the latest reports the sale of Advanced Rehabilitation and describes restorative therapies around fracture care.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 5, 2026Pain Treatments is comprised of non-surgical joint pain injection therapies as well as peripheral nerve stimulation (“PNS”) products to…View ↗
Competes with Ferring Pharmaceutical, Fidia Farmaceutici, Johnson & Johnson, Zimmer Biomet Holdings, Arthrex, Emcyte, Channel-Markers Medical, SPR Therapeutics, Nalu, Curonix, Medtronic, DePuy Orthopaedics, Stryker, NuVasive, Orthofix Medical, Globus Medical, Integra Life Sciences, Söering, Enovis, and XFT Medical
10-K for FY2025, filed Mar 5, 2026Our Pain Treatments that we own or distribute compete with products from Ferring Pharmaceutical Inc., Fidia Farmaceutici S.p.A., Johnson &…View ↗
Loading...